IL6 and non-small cell lung carcinoma: Across two studies of patients with recurrent or advanced NSCLC receiving αPD‐1 agents, patients with higher plasma IL‐6 concentrations (>6.37 pg/mL or >11.15 pg/mL, respectively) had shorter progression‐free survival (PFS).25, 26